Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ajay Manaithiya"'
Autor:
Ajay Manaithiya, Ratul Bhowmik, Satarupa Acharjee, Sameer Sharma, Sunil Kumar, Mohd. Imran, Bijo Mathew, Seppo Parkkila, Ashok Aspatwar
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 23, Iss , Pp 2811-2836 (2024)
We developed a bio-cheminformatics method, exploring disease inhibition mechanisms using machine learning-enhanced quantitative structure-activity relationship (ML-QSAR) models and knowledge-driven neural networks. ML-QSAR models were developed using
Externí odkaz:
https://doaj.org/article/41ba6517bac94e959549abd5e53701f8
Autor:
Ajay Manaithiya, Ratul Bhowmik, Kunal Bhattacharya, Rajarshi Ray, Sagar Singh Shyamal, Fabrizio Carta, Claudiu T. Supuran, Seppo Parkkila, Ashok Aspatwar
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundMycobacterium tuberculosis (Mtb) carbonic anhydrases (CAs) are critical enzymes that regulate pH by converting CO2 to HCO3−, essential for Mtb’s survival in acidic environments. Inhibiting γ-CAs presents a potential target for novel an
Externí odkaz:
https://doaj.org/article/e1770d03d4f74e38ba37ffcb73779f6e
Autor:
Abeer Mohammad, Ahmed Zheoat, Amjad Oraibi, Ajay Manaithiya, Khalid S. Almaary, Hiba Allah Nafidi, Mohammed Bourhia, Soumaya Kilani-Jaziri, Yousef A. Bin Jardan
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2024)
Introduction: The pursuit of effective therapeutic solutions for SARS-CoV-2 infections and COVID-19 necessitates the repurposing of existing compounds. This study focuses on the detailed examination of the central protease, 3-chymotrypsin-like protea
Externí odkaz:
https://doaj.org/article/e7bda16b8ae14986a424263a2ec0a600
Autor:
Ratul Bhowmik, Ravi Kant, Ajay Manaithiya, Daman Saluja, Bharti Vyas, Ranajit Nath, Kamal A. Qureshi, Seppo Parkkila, Ashok Aspatwar
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/d7e6b29b185a495fbc826e06b9720edf
Autor:
Ratul Bhowmik, Ravi Kant, Ajay Manaithiya, Daman Saluja, Bharti Vyas, Ranajit Nath, Kamal A. Qureshi, Seppo Parkkila, Ashok Aspatwar
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Mycobacterium tuberculosis is the bacterial strain that causes tuberculosis (TB). However, multidrug-resistant and extensively drug-resistant tuberculosis are significant obstacles to effective treatment. As a result, novel therapies against various
Externí odkaz:
https://doaj.org/article/0e6913ceb93546f4a8db90da3b6c8fa0
Autor:
Vishal Mathur, Ozair Alam, Nadeem Siddiqui, Mukund Jha, Ajay Manaithiya, Sandhya Bawa, Naveen Sharma, Sultan Alshehri, Prawez Alam, Faiyaz Shakeel
Publikováno v:
Molecules, Vol 28, Iss 15, p 5860 (2023)
This article sheds light on the various scaffolds that can be used in the designing and development of novel synthetic compounds to create DPP-4 inhibitors for the treatment of type 2 diabetes mellitus (T2DM). This review highlights a variety of scaf
Externí odkaz:
https://doaj.org/article/f105df4c4791492d8df892a4474ef50a
Autor:
Md. Jahangir Alam, Ozair Alam, Mohd. Javed Naim, Farah Nawaz, Ajay Manaithiya, Mohd Imran, Hamdy Khamees Thabet, Sultan Alshehri, Mohammed M. Ghoneim, Prawez Alam, Faiyaz Shakeel
Publikováno v:
Molecules, Vol 27, Iss 24, p 8708 (2022)
Pyrazole, an important pharmacophore and a privileged scaffold of immense significance, is a five-membered heterocyclic moiety with an extensive therapeutic profile, viz., anti-inflammatory, anti-microbial, anti-anxiety, anticancer, analgesic, antipy
Externí odkaz:
https://doaj.org/article/6c78b83607334a1291573b824dfbe948
Publikováno v:
Journal of Biomolecular Structure and Dynamics. :1-26
Pharmacophore modelling, 3 D QSAR modelling, virtual screening, and molecular dynamics study, all-in-one combination were employed successfully design and develop an alpha-glucosidase inhibitor. To explain the structural prerequisites of biologically
Autor:
Ratul Bhowmik, Ajay Manaithiya, Bharti Vyas, Ranajit Nath, Sara Rehman, Shubham Roy, Ratna Roy
Publikováno v:
Structural Chemistry. 33:815-831
Publikováno v:
Archiv der Pharmazie. 356
The α-glucosidase is a validated target to develop drugs for treating type 2 diabetes mellitus. The existing α-glucosidase inhibitors have certain shortcomings related to side effects and route of synthesis. Accordingly, it is inevitable to develop